Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus
Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day). Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin. Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.
Main Authors: | , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Endocrinologia e Metabologia
2014
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302014000400369 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0004-27302014000400369 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0004-273020140004003692014-06-13Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitusBarros,Joelma Ines TagliapietraFechine,Francisco VagnaldoMontenegro Júnior,Renan MagalhãesVale,Otoni Cardoso doFernandes,Virgínia OliveiraSouza,Marcellus Henrique Loiola Ponte deCunha,Gilmara Holanda daMoraes,Manoel Odorico ded?Alva,Catarina BrasilMoraes,Maria Elisabete Amaral de Diabetes mellitus type 2 dipeptidyl-peptidase IV inhibitors incretins diabetes complications Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day). Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin. Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control. info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArquivos Brasileiros de Endocrinologia & Metabologia v.58 n.4 20142014-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302014000400369en10.1590/0004-2730000002914 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Barros,Joelma Ines Tagliapietra Fechine,Francisco Vagnaldo Montenegro Júnior,Renan Magalhães Vale,Otoni Cardoso do Fernandes,Virgínia Oliveira Souza,Marcellus Henrique Loiola Ponte de Cunha,Gilmara Holanda da Moraes,Manoel Odorico de d?Alva,Catarina Brasil Moraes,Maria Elisabete Amaral de |
spellingShingle |
Barros,Joelma Ines Tagliapietra Fechine,Francisco Vagnaldo Montenegro Júnior,Renan Magalhães Vale,Otoni Cardoso do Fernandes,Virgínia Oliveira Souza,Marcellus Henrique Loiola Ponte de Cunha,Gilmara Holanda da Moraes,Manoel Odorico de d?Alva,Catarina Brasil Moraes,Maria Elisabete Amaral de Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus |
author_facet |
Barros,Joelma Ines Tagliapietra Fechine,Francisco Vagnaldo Montenegro Júnior,Renan Magalhães Vale,Otoni Cardoso do Fernandes,Virgínia Oliveira Souza,Marcellus Henrique Loiola Ponte de Cunha,Gilmara Holanda da Moraes,Manoel Odorico de d?Alva,Catarina Brasil Moraes,Maria Elisabete Amaral de |
author_sort |
Barros,Joelma Ines Tagliapietra |
title |
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus |
title_short |
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus |
title_full |
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus |
title_fullStr |
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus |
title_full_unstemmed |
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus |
title_sort |
effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus |
description |
Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day). Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin. Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control. |
publisher |
Sociedade Brasileira de Endocrinologia e Metabologia |
publishDate |
2014 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302014000400369 |
work_keys_str_mv |
AT barrosjoelmainestagliapietra effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT fechinefranciscovagnaldo effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT montenegrojuniorrenanmagalhaes effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT valeotonicardosodo effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT fernandesvirginiaoliveira effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT souzamarcellushenriqueloiolapontede effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT cunhagilmaraholandada effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT moraesmanoelodoricode effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT dalvacatarinabrasil effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus AT moraesmariaelisabeteamaralde effectoftreatmentwithsitagliptinonsomatosensoryevokedpotentialsandmetaboliccontrolinpatientswithtype2diabetesmellitus |
_version_ |
1756372770769338368 |